Compare Incyte Corporation (INCY) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Sea Limited — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Sea Limited trades at $131.4 (market cap $80.55B). The key difference: Sea Limited is far larger — about 3.3× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals.
| INCY | SE | |
|---|---|---|
Market Cap | $24.54B | $80.55B |
Sector | Health | Media |
52-Week High | $129.93 | $196.50 |
52-Week Low | $81.61 | $78.16 |
Enterprise Value | $20.04B | $75.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
SE stock trades at $129.71, up 12.99% on strong Q2 2026 results, with revenue of $7.8 billion (up 48% year-over-year) and net income of $458 million (up 11%). The technical picture is bullish with moving averages supporting the uptrend, though RSI levels indicate overbought conditions. Fundamentals show robust revenue growth and improving profitability, with net income margin reaching 6.36% in 2025. Analyst sentiment remains positive with a consensus buy rating and $128.33 price target.
The outlook for SE is favorable given accelerating growth across e-commerce, fintech, and gaming segments, but risks include margin pressure from increased investments and credit costs. The stock's high valuation multiples (P/E of 50.78) require sustained execution to justify further gains. Near-term resistance lies at $133, with support at $128.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
